United BioSource Corporation Acquires Total Healthcare Group
United BioSource Corporation
(UBC), a wholly owned subsidiary of Medco Health Solutions, Inc., today announced the acquisition of Total Healthcare Group (THG), a London-based international consultancy serving clients in the biopharmaceutical industry. THG provides global payer research, strategic planning, and global value dossiers for biopharmaceutical products.
THG, together with UBC’s existing value strategy and research services, will be led by THG’s Dr. Robert Hollamby, who has been appointed Senior Vice President at UBC.
“Demonstrating value and providing evidence-based research that allows stakeholders in the health care market to make important economic decisions surrounding biopharmaceuticals and devices is crucial in the market place,” said UBC President Mark Clein. “UBC helps clients respond effectively to the evolving health care environment by researching, communicating, and demonstrating value in medicines. The addition of THG significantly expands our capabilities and geographic reach and allows us to launch a comprehensive practice that we expect to be a leader in the global biopharmaceutical industry.”
Results International served as THG’s financial advisor in this transaction.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
